Anker, Stefan D.
Anker, Stefan
Stefan D. Anker German cardiologist
VIAF ID: 311285869 ( Personal )
Permalink: http://viaf.org/viaf/311285869
Preferred Forms
- 100 1 _ ‡a Anker, Stefan
-
-
- 100 1 _ ‡a Anker, Stefan D.
-
- 100 1 _ ‡a Anker, Stefan D.
-
- 100 1 _ ‡a Anker, Stefan D.
-
- 100 0 _ ‡a Stefan D. Anker ‡c German cardiologist
4xx's: Alternate Name Forms (10)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
The @ESC textbook of heart failure | |
Aktualny stan wiedzy na temat statyn | |
Anämie bei chronischer Herzinsuffizenz | |
Andropausal syndrome in men with systolic heart failure | |
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? : evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry | |
Atorvastatin modulates constitutive and lipopolysaccharide induced IL-6 secretion in precursors of human skeletal muscle | |
Atrial fibrillation in chronic non-cardiac disease : where do we stand? | |
Atrial natriuretic peptide and related peptides | |
The burden of chronic obstructive pulmonary disease in patients hospitalizedwith heart failure | |
Cachexia as a major public health problem : frequent, costly, and deadly | |
Cachexia: common, deadly, with and urgent need for precise definition and new therapies | |
Cardiac cachexia : a systematic overview | |
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure | |
Current state of knowledge about statins / Stefan D. Anker, Stephan von Haehling. - Poznań, 2007. | |
The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers : a randomized study | |
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology | |
Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease | |
Guideline adherence in treatment of COPD | |
Heart failure and sleep‐disordered breathing : susceptibility to reduced muscle strength and preclinical congestion (SICA‐HF cohort) | |
Heart failure prevalence in the general population SOBOTA-HF study rationale and design | |
The impact of irbesartan on impaired insulin sensitivity in chronic heart failure - results from a placebo-controlled, double blinded, randomized proof of concept-trial | |
The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies investigating co-morbidities aggravating heart failure | |
impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM‐CHF randomized controlled trial | |
Implementation of guidelines improves mortality in patients admitted in community hospital for decompensated chronic heart failure | |
Improving care for patients with acute heart failure, 2014: | |
Inflammatory biomarkers in heart failure revisited : much more than innocent bystanders | |
Influence of cancer cachexia on drug liver metabolism and renal elimination in rats | |
Initation of treatment with carvedilol or bisoprolol and changes in body fat mass in patients with chronic heart failure | |
Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure | |
Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring | |
Mechanism and novel therapeutic approaches to wasting in chronic disease | |
Neurohormonal activation and inflammation in c hronic cardiopulmonary disease: a brief systematic review | |
Neurological and endocrinological disorders : orphans in chronic obstructive pulmonary disease | |
No train, no gain: Does this apply to heart failure with preserved ejection fraction? | |
Nutritional indices, weight change, and mortality in heart failure : the nutrition Day survey analysis | |
Nutritional status, nutritional intake, and mortality in adult hospitalized patients : results of a European-wide NutritionDay survey | |
The obesity paradox in chronic disease : facts and numbers | |
Overcoming barriers to timely recognition and treatment of cancer cachexia: Sharing Progress in Cancer Care Task Force Position Paper and Call to Action | |
Pentoxifzlline increases hemoglobin in anemic patients with chronic heart failure | |
Pharmacokinetics of drugs in cachectic patients: a systematic review | |
Pharmacotherapy of cachexia | |
Prognostic factors in chronic heart failure | |
Prognostic role of body mass index after acute mypcardial infarction | |
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF) | |
Pulmonary function during beta-blocker titration in elderly patients with heart failure: the CIBIS-ELD analysis | |
PURE muscle and more | |
Relation of longitudinal changes in quality of life assessments to changes in functional capacity in patients with heart failure with and without anemia | |
The relationship between serum lipids and survival in patients hospitalized with heart failure | |
Role of cardiopulmonary exercise testing in clinical stratification in heart failure. | |
Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia | |
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world | |
Self-rated health predicts adverse events during beta-blocker treatment : the CIBIS-ELD randomised trial analysis | |
Sibutramine in cardiovascular disease: is SCOUT the new STORM on the horizon? | |
Smoking cessation in heart failure : easier said than done | |
Stosowanie statyn w niewydolności serca | |
Subgroup or selection bias? | |
Type 2 diabetes mellitus and heart failure : a position statement from the Heart Failure Association of the European Society of Cardiology | |
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes : data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry | |
Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications | |
What does the lay public know about heart failure? Findings from the Heart failure awareness day initiative | |
Wpływ wyniszczenia na przeżycie chorych na nowotwory, niewydolność serca i inne przewlekłe choroby | |
Wytyczne European Society of Cardiology dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku |